{"id":2535,"date":"2014-10-18T12:48:01","date_gmt":"2014-10-18T12:48:01","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2535"},"modified":"2014-10-18T12:48:01","modified_gmt":"2014-10-18T12:48:01","slug":"statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/","title":{"rendered":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko"},"content":{"rendered":"<p>AMB 2010, 44, 84 Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko Der g\u00fcnstige Effekt der Statine in der Sekund\u00e4rpr\u00e4vention \u2013 also bei Patienten mit manifester kardiovaskul\u00e4rer Erkrankung \u2013 ist unumstritten. Nicht so eindeutig ist die Studienlage zu ihrem Einsatz in der Prim\u00e4rpr\u00e4vention, zumal es nur wenige Studien gibt, in denen tats\u00e4chlich [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2010, 44, 84 Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko Der g\u00fcnstige Effekt der Statine in der Sekund\u00e4rpr\u00e4vention \u2013 also bei Patienten mit manifester kardiovaskul\u00e4rer Erkrankung \u2013 ist unumstritten. Nicht so eindeutig ist die Studienlage zu ihrem Einsatz in der Prim\u00e4rpr\u00e4vention, zumal es nur wenige Studien gibt, in denen tats\u00e4chlich [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[1523,1524,76,1525,1526,1527,109,110,237,78,111,238,1528,1529,79,112,239,1530,74,242,1531,1532,244,245,113,1533],"class_list":["post-2535","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-afcaps-studie","tag-allhat-studie","tag-angina-pectoris","tag-ascot-studie","tag-aspen-studie","tag-cards-studie","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-fluvastatin","tag-herzinfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-hyrim-studie","tag-jupiter-studie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-lovastatin","tag-mega-studie","tag-myokardinfarkt","tag-pravastatin","tag-prevend-it-studie","tag-prosper-studie","tag-rosuvastatin","tag-simvastatin","tag-statine","tag-woscops-studie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko<\/title>\n<meta name=\"description\" content=\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko\" \/>\n<meta property=\"og:description\" content=\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-18T12:48:01+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko\",\"datePublished\":\"2014-10-18T12:48:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/\"},\"wordCount\":1031,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"AFCAPS-Studie\",\"ALLHAT-Studie\",\"Angina pectoris\",\"ASCOT-Studie\",\"ASPEN-Studie\",\"CARDS-Studie\",\"Cholesterinsynthese-Hemmer\",\"CSE-Hemmer\",\"Fluvastatin\",\"Herzinfarkt\",\"HMG-CoA-Reduktase-Hemmer\",\"Hypercholesterin\u00e4mie\",\"HYRIM-Studie\",\"JUPITER-Studie\",\"Koronare Herzkrankheit\",\"Lipidsenker\",\"Lovastatin\",\"MEGA-Studie\",\"Myokardinfarkt\",\"Pravastatin\",\"PREVEND IT-Studie\",\"PROSPER-Studie\",\"Rosuvastatin\",\"Simvastatin\",\"Statine\",\"WOSCOPS-Studie\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/\",\"name\":\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-10-18T12:48:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko","description":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/","og_locale":"de_DE","og_type":"article","og_title":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko","og_description":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-10-18T12:48:01+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko","datePublished":"2014-10-18T12:48:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/"},"wordCount":1031,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["AFCAPS-Studie","ALLHAT-Studie","Angina pectoris","ASCOT-Studie","ASPEN-Studie","CARDS-Studie","Cholesterinsynthese-Hemmer","CSE-Hemmer","Fluvastatin","Herzinfarkt","HMG-CoA-Reduktase-Hemmer","Hypercholesterin\u00e4mie","HYRIM-Studie","JUPITER-Studie","Koronare Herzkrankheit","Lipidsenker","Lovastatin","MEGA-Studie","Myokardinfarkt","Pravastatin","PREVEND IT-Studie","PROSPER-Studie","Rosuvastatin","Simvastatin","Statine","WOSCOPS-Studie"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/","name":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-10-18T12:48:01+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/statine-in-der-kardiovaskulaeren-primaerpraevention-kein-nutzen-bei-niedrigem-risiko\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Statine in der kardiovaskul\u00e4ren Prim\u00e4rpr\u00e4vention \u2013 kein Nutzen bei niedrigem Risiko"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2535"}],"version-history":[{"count":2,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2535\/revisions"}],"predecessor-version":[{"id":2537,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2535\/revisions\/2537"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}